DEXAMETHASONE SODIUM PHOSPHATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	DEXAMETHASONE SODIUM PHOSPHATE	dexamethasone sodium phosphate	INJECTABLE;INJECTION	208689	ANDA	Amneal Pharmaceuticals LLC	70121-1450-5	25 VIAL, SINGLE-DOSE in 1 CARTON (70121-1450-5) / 1 mL in 1 VIAL, SINGLE-DOSE (70121-1450-1)	2018-08-27
Amneal	DEXAMETHASONE SODIUM PHOSPHATE	dexamethasone sodium phosphate	INJECTABLE;INJECTION	208689	ANDA	Amneal Pharmaceuticals LLC	70121-1451-5	25 VIAL, MULTI-DOSE in 1 CARTON (70121-1451-5) / 5 mL in 1 VIAL, MULTI-DOSE (70121-1451-1)	2018-08-27
Amneal	DEXAMETHASONE SODIUM PHOSPHATE	dexamethasone sodium phosphate	INJECTABLE;INJECTION	208689	ANDA	Amneal Pharmaceuticals LLC	70121-1452-1	1 VIAL, MULTI-DOSE in 1 CARTON (70121-1452-1) / 30 mL in 1 VIAL, MULTI-DOSE	2018-08-27
Eugia Pharma	DEXAMETHASONE SODIUM PHOSPHATE	dexamethasone sodium phosphate	INJECTABLE;INJECTION	206781	ANDA	A-S Medication Solutions	50090-3300-0	25 VIAL, MULTI-DOSE in 1 CARTON (50090-3300-0) / 30 mL in 1 VIAL, MULTI-DOSE	2015-12-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Dexamethasone sodium phosphate is a corticosteroid used to treat various conditions, including inflammation and allergic responses. Its critical role in treating severe COVID-19 cases has increased demand and highlighted supply chain vulnerabilities. This analysis examines key suppliers, manufacturing capabilities, regulatory considerations, and potential risks associated with the dexamethasone sodium phosphate supply chain.

Who are the Primary Manufacturers of Dexamethasone Sodium Phosphate API?

The active pharmaceutical ingredient (API) manufacturing for dexamethasone sodium phosphate is concentrated among a limited number of global suppliers. These companies possess the specialized chemical synthesis capabilities and regulatory compliance required for pharmaceutical production.

Key API manufacturers include:

Diosynth Biotechnologies: A subsidiary of International Flavors & Fragrances (IFF), Diosynth is a significant producer of complex APIs, including corticosteroids. They operate multiple manufacturing sites in the United States and Europe.
Hubei Biocause Pharmaceutical Co., Ltd.: A China-based company specializing in steroid hormones and APIs. They are a major global supplier of various corticosteroid APIs.
Zhejiang Huahai Pharmaceutical Co., Ltd.: Another prominent Chinese pharmaceutical company with substantial API production capacity, including dexamethasone sodium phosphate.
Bristol Myers Squibb: While also a finished drug manufacturer, BMS has historically had API manufacturing capabilities for certain products, though their current role as a primary independent API supplier for dexamethasone sodium phosphate requires verification.
BASF Pharma: A division of BASF, a chemical giant, that produces pharmaceutical ingredients. Their involvement would typically be through specialized synthesis of complex molecules.
Pfizer CentreOne: The contract development and manufacturing organization (CDMO) arm of Pfizer, capable of producing APIs for various therapeutic areas.

Table 1: Selected Dexamethasone Sodium Phosphate API Suppliers and Locations

Supplier	Primary Location(s)	Product Focus	Notes
Hubei Biocause Pharmaceutical Co., Ltd.	China	Corticosteroid APIs	High-volume producer.
Zhejiang Huahai Pharmaceutical Co., Ltd.	China	Steroid APIs	Significant global exporter.
Diosynth Biotechnologies	USA, Netherlands	Complex APIs, Corticosteroids	Focus on specialized synthesis.
BASF Pharma	Germany	Pharmaceutical Ingredients	Broad chemical and pharmaceutical portfolio.
Pfizer CentreOne	USA, Europe	CDMO Services	Broad API manufacturing capabilities.

These companies operate under stringent Good Manufacturing Practices (GMP) regulations enforced by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The geographic concentration of API production, particularly in China, presents inherent supply chain risks due to geopolitical factors, regulatory changes, and potential disruptions.

What are the Key Finished Dosage Form (FDF) Manufacturers?

Finished dosage form manufacturers convert the API into the final drug products (e.g., injectable solutions, tablets). These companies often have a global presence and extensive distribution networks.

Major FDF manufacturers utilizing dexamethasone sodium phosphate include:

Fresenius Kabi: A global healthcare company specializing in infusion therapy and clinical nutrition. They are a significant producer of injectable dexamethasone sodium phosphate. Their manufacturing facilities are located in various countries, including Germany, the United States, and Brazil.
Baxter International: Another large provider of critical care products, including injectable drugs. Baxter manufactures dexamethasone sodium phosphate injections at its facilities.
Hikma Pharmaceuticals: A multinational pharmaceutical company that manufactures and distributes a wide range of generic and branded products, including injectable corticosteroids.
Merck & Co. (MSD): While primarily known for branded pharmaceuticals, Merck also produces generic injectable formulations, including dexamethasone sodium phosphate, through its generics division or partnerships.
Amneal Pharmaceuticals: A U.S.-based pharmaceutical company with capabilities in developing and manufacturing generic injectable products.
Teva Pharmaceutical Industries: A leading global generic drug manufacturer with extensive formulation and manufacturing capabilities worldwide.

The regulatory approval for an FDF product requires not only the API to meet specifications but also the final formulation and manufacturing process to adhere to GMP. This involves bioequivalence studies and stability testing.

What are the Regulatory Requirements for Dexamethasone Sodium Phosphate Production?

Production of dexamethasone sodium phosphate, both as an API and an FDF, is subject to rigorous regulatory oversight. Compliance is critical for market access and patient safety.

Key regulatory aspects include:

Good Manufacturing Practices (GMP): Adherence to GMP guidelines is mandatory. These guidelines cover all aspects of production, from facility design and equipment to personnel training and quality control. The FDA's 21 CFR Part 210 and 211, and the EMA's EudraLex Volume 4, are primary references.
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit these confidential documents to regulatory agencies, detailing the manufacturing process, quality controls, and specifications. FDF manufacturers reference these DMFs/ASMFs in their marketing authorization applications.
Site Inspections: Regulatory agencies, such as the FDA and EMA, conduct routine inspections of manufacturing facilities to ensure ongoing compliance with GMP.
Quality Control Testing: Extensive testing is required for raw materials, in-process samples, and the final API and FDF. This includes identity, purity, potency, and impurity profiling.
Impurity Profiling: Identifying and controlling impurities is paramount. Regulatory guidelines, such as ICH Q3A (R2) and Q3B (R2), set thresholds for reporting, identifying, and qualifying impurities. Specific attention is paid to genotoxic impurities.
Stability Studies: Manufacturers must conduct studies to determine the shelf life of the drug product under various storage conditions, as per ICH Q1A (R2).
Marketing Authorization Applications (MAA): FDF manufacturers must submit comprehensive dossiers (e.g., Common Technical Document - CTD) to regulatory authorities for approval before marketing the drug. This includes detailed information on the API, formulation, manufacturing, and clinical data.
Post-Market Surveillance: Continuous monitoring of product quality and safety after approval is required, including adverse event reporting.

The regulatory landscape can vary by region. For example, while the FDA and EMA have harmonized standards in many areas, specific national requirements may exist.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The dexamethasone sodium phosphate supply chain faces several risks that could impact availability.

Key Risks:

Geographic Concentration: A significant portion of API production is located in China. This concentration creates vulnerability to trade disputes, natural disasters, pandemics, or political instability in the region.
Raw Material Sourcing: The synthesis of dexamethasone sodium phosphate relies on upstream chemical precursors. Disruptions in the supply of these raw materials, which may also be concentrated geographically, can halt API production.
Manufacturing Capacity Constraints: While demand has increased, rapidly scaling up specialized API and FDF manufacturing can be challenging due to lead times for equipment, facility expansion, and skilled personnel.
Quality Issues and Recalls: Any lapse in GMP compliance can lead to product recalls, disrupting supply and damaging a manufacturer's reputation. Regulatory actions, such as import alerts, can halt product flow into major markets.
Logistical Challenges: Global transportation disruptions, including shipping delays, port congestion, and air freight availability, can impact the timely delivery of both API and FDF.
Intellectual Property (IP) and Regulatory Hurdles: While dexamethasone sodium phosphate is a well-established molecule, patents related to novel formulations, delivery methods, or specific manufacturing processes can influence market dynamics.
Geopolitical Tensions: Trade restrictions, tariffs, or sanctions imposed between major producing and consuming nations can disrupt established supply routes.

Mitigation Strategies:

Supplier Diversification: Pharmaceutical companies are increasingly seeking to diversify their API and FDF supplier base, establishing relationships with manufacturers in different geographic regions to reduce reliance on single sources.
Dual Sourcing: Qualifying multiple suppliers for critical raw materials and APIs provides a backup in case of disruption from one supplier.
Inventory Management: Maintaining strategic safety stocks of API and critical finished drug products can buffer against short-term supply interruptions.
Supply Chain Visibility and Monitoring: Implementing robust supply chain management systems that provide real-time visibility into inventory levels, production schedules, and logistics allows for proactive identification and response to potential issues.
CDMO Partnerships: Engaging with Contract Development and Manufacturing Organizations (CDMOs) can provide flexible manufacturing capacity and specialized expertise, aiding in scaling production when needed.
Regulatory Engagement: Maintaining open communication with regulatory agencies and proactive compliance ensures that manufacturing sites meet evolving standards and reduces the risk of regulatory enforcement actions.
Contingency Planning: Developing detailed business continuity and disaster recovery plans for critical supply points is essential.
Regional Manufacturing Hubs: Encouraging and supporting the development of API and FDF manufacturing capabilities in diverse geographic regions can reduce global supply chain risks.

What is the Market Outlook for Dexamethasone Sodium Phosphate?

The market for dexamethasone sodium phosphate has experienced significant growth, primarily driven by its use in treating severe COVID-19. While the acute phase of the pandemic has subsided, the established role of dexamethasone in critical care and its continued use for other inflammatory conditions ensure sustained demand.

COVID-19 Impact: The RECOVERY trial, published in June 2020, demonstrated a mortality benefit for dexamethasone in mechanically ventilated patients, leading to a surge in demand and prompting regulatory agencies to expedite reviews and monitor supply.
Established Indications: Dexamethasone sodium phosphate remains a cornerstone treatment for a wide range of inflammatory and autoimmune diseases, including arthritis, asthma, severe allergies, and certain types of cancer. This core demand is relatively stable.
Generic Market: Dexamethasone sodium phosphate is largely a generic drug, meaning competition is based on price and supply reliability. Manufacturers with efficient production processes and robust supply chains are well-positioned.
Future Growth Drivers: Potential new indications or improved delivery formulations could drive future market growth. However, significant patent expirations for the molecule itself limit opportunities for novel brand-name market exclusivity.

The market is characterized by a balance between established, stable demand from its traditional therapeutic uses and the more volatile, but significant, demand driven by public health emergencies. Ensuring supply chain resilience is therefore a key strategic imperative for manufacturers and healthcare systems.

Key Takeaways

Dexamethasone sodium phosphate API manufacturing is concentrated among a few global suppliers, primarily in China.
Finished dosage form manufacturing is more diversified, involving numerous multinational pharmaceutical companies.
Strict regulatory compliance, including GMP, is essential at all stages of production.
Supply chain risks include geographic concentration, raw material sourcing issues, and capacity constraints.
Mitigation strategies involve supplier diversification, dual sourcing, and enhanced supply chain visibility.
Market outlook indicates sustained demand due to established therapeutic uses and potential for future growth in critical care.

Frequently Asked Questions

What specific regulatory agencies oversee dexamethasone sodium phosphate production? Regulatory oversight is primarily by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and equivalent national regulatory bodies in other countries.
How long does it typically take to qualify a new API supplier for dexamethasone sodium phosphate? Qualifying a new API supplier is a multi-step process that can take 12 to 18 months or longer, involving rigorous quality audits, process validation, and submission of regulatory documentation.
What are the main chemical precursors used in the synthesis of dexamethasone sodium phosphate? The synthesis involves complex multi-step organic chemistry, often starting from steroidal intermediates derived from diosgenin or other natural sources, followed by specific chemical modifications. Precise precursor lists are proprietary to manufacturers.
Are there any specific quality control tests that are particularly critical for dexamethasone sodium phosphate? Critical quality control tests include assays for potency, identification, purity (especially related substances and residual solvents), and microbial limits, ensuring the absence of harmful contaminants.
What are the typical storage conditions for dexamethasone sodium phosphate API and FDF? API and FDF storage conditions are specified by the manufacturer based on stability data, but generally, they require protection from light and moisture, with controlled room temperature or refrigerated storage depending on the specific formulation.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice for Finished Pharmaceuticals. 21 CFR Part 211. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211

[2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4. Good Manufacturing Practice (GMP) Guidelines. Retrieved from https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2). Retrieved from https://www.ich.org/page/quality-guidelines

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Impurities in New Drug Products Q3B(R2). Retrieved from https://www.ich.org/page/quality-guidelines

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). Retrieved from https://www.ich.org/page/quality-guidelines

[6] Horby, P. W., Lim, W. S., Robertson, C., Snowden, N., & Amadi, A. (2020). Dexamethasone in hospitalized patients with COVID-19 — preliminary report. The New England Journal of Medicine, 383(10), 998-1000.

[7] COVID-19 Clinical Network. (2020, June 17). Dexamethasone reduces the risk of death in hospitalised patients with COVID-19. University of Oxford. Retrieved from https://www.ox.ac.uk/news/2020-06-17-dexamethasone-reduces-risk-death-hospitalised-patients-covid-19

Suppliers and packagers for generic pharmaceutical drug: DEXAMETHASONE SODIUM PHOSPHATE